diabetes Diabetes mellitus
Conditions
Interventions
Gut microbiota
Imidazole propionate
Diabetes mellitus
We will orally administrate labelled histidine twice (either using gelatin
capsules that are releasing histidine in the small intestine versus
ColoPulse-capsules that release histidine in the colon)
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: All subjects: age 18-54 years old, caucasian male, able to give informed consent;- Healthy controls: Subjects do not meet the criteria for metabolic syndrome or diabetes type 2, BMI 102 cm, HDL-cholesterol 11.1 mmol/L and/or a fasting blood glucose level of >7.0 mmol/L and/or a blood sugar glucose of >11.1mmol/L two hours after an oral glucose toleralance test and/or an HbA1c of >47mmol/mol. Stable metformin use for at least 1 month (preferably 3dd 500mg)
Exclusion criteria
Exclusion criteria: All subjects: - Cholecystectomy - A history of cardiovascular event (MI or pacemaker implantation) - Use of medication in the last three months with the exception of metformin for DM2 subjects - (expected) prolonged compromised immunity (due to recent cytotoxic chemotherapy or HIV infection with a CD4 count
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary objective will be determination of plasma and 24h fecal concentrations of labelled L-histidine and its degradation products, urocanate, IP and glutamate upon either ingestion of gelatin capsules (thus small intestinal release) or colopulse capsules (colonic release). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary objective will be differences in uptake and production between subjects with a normal and impaired insulin sensitivity as well as in DM2 subjects on stable dose of oral metformin in relation to fecal microbiota composition. | — |
Countries
The Netherlands
Outcome results
None listed